

Immuron Limited
(ASX: IMC)

RESULTS OF ANNUAL GENERAL MEETING

Friday 29th November 2013

The Company wishes to advise that all resolutions were carried on show of hands.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the resolutions considered by Members of the Company at the Annual General Meeting held today.

Resolution	For	Against	Abstain	Proxy's Discretion*	Total Valid Proxies Received
1 Adoption of Remuneration Report	238,174,139	2,945,786	64,492,498	169,534,561	475,146,984
2 Election of Daniel Pollock as a Director	189,334,855	694,481	65,583,087	219,534,561	475,146,984
3 Election of Stephen Anastasiou as a Director	195,752,848	695,481	109,164,094	169,534,561	475,146,984
4 Approve the issue of 8,750,000 Shares to Grandlodge Pty Ltd	195,467,295	60,145,128	168,326,929	51,207,632	475,146,984
5 Approve the issue of 2,604,167 Shares and 20,000,000 Options to Roger Aston	195,467,295	981,034	59,164,094	219,534,561	475,146,984
6 Approve the issue of 1,875,000 Shares and 10,000,000 Options to Daniel Pollock	189,048,302	60,145,128	6,418,993	219,534,561	475,146,984
7 Approve the issue of 10,000,000 Options to Stephen Anastasiou	195,467,295	60,145,128	50,000,000	169,534,561	475,146,984
8 Approve the issue of 5,000,000 Shares and 10,000,000 Options to The CFO Solution	252,131,389	981,034	2,500,000	219,534,561	475,146,984
9 Appointment of William Buck Audit (VIC) Pty Ltd as the Company's auditor	255,279,892	238,245	94,286	219,534,561	475,146,984
10 Approval of additional capacity to issue Shares under ASX Listing Rule 7.1A	188,932,387	66,680,036	-	219,534,561	475,146,984

* The Chairman voted undirected proxies in his control in favour of all resolutions.

On behalf of the Board



Phillip Hains
Company Secretary

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron's products will be expedited. Immuron's current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver/NASH, and influenza. Immuron has a product in the market, Travelan, for preventing travellers' diarrhoea.